Transaction terms include an undisclosed upfront cash payment plus development milestones, for up to $202 million total consideration, with no additional financial details disclosed. Engage’s ...
In April, FDA announced plans for a pilot program to allow for real-time data review during clinical trials. 1 The program ...
Sandra Coufal, MD, CEO of Toragen, says the company is positioning its HPV E5 inhibitor TGN-S15 not as a competitor to Merck’s Keytruda, but as a combination partner designed to enhance checkpoint ...
Violet’s seed extension supports IND-enabling studies of an EphB3 inhibitor to modulate microglia–astrocyte crosstalk and promote glial-mediated synaptic preservation in Alzheimer’s disease. Full-Life ...
In April, FDA announced plans for a pilot program to allow for real-time data review during clinical trials. 1 The program ...
Regeneron and Parabilis Medicines partner to discover and develop antibody-Helicon conjugates, aiming to create a new class ...
Toragen CEO Sandra Coufal, MD, discusses why the company is targeting HPV’s overlooked E5 protein, positioning its small-molecule therapy as a potential complement to checkpoint inhibitors like ...
Makary’s departure followed internal disputes over approval decisions and Covid-19 vaccine posture, catalyzing a rapid ...
Mike Petroutsas, president and head of U.S. commercial at Astellas, explores the importance of insight-driven ...
Dr. Richard Graham explains how FDA’s new program allows for the usage of real-time data during clinical trials. In April, ...
Biotech’s ~10-year path from private risk to approved therapy is mismatched with trading-driven capital markets, where minor ...
In today’s Pharmaceutical Executive Daily, the FDA grants breakthrough therapy designation to baxdrostat for uncontrolled hypertension, a wave of leadership departures leaves the FDA facing renewed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results